Long-Term Results of Hepatectomy for Patients with Alveolar Echinococcosis: A Single-Center Experience

详细信息    查看全文

• 作者：Norio Kawamura MD^a ; ^{noriwon@mist.ocn.ne.jp"" rel=""nofollow} ; Toshiya Kamiyama MD^a ; Naoki Sato MD^a ; Kazuaki Nakanishi MD^a ; Hideki Yokoo MD^a ; Hirofumi Kamachi MD^a ; Munenori Tahara MD^a ; Shoji Yamaga MD^a ; Michiaki Matsushita MD^b ; Satoru Todo MD ; FACS^a
• 刊名：Journal of the American College of Surgeons
• 出版年：2011
• 出版时间：May 2011
• 年：2011
• 卷：212
• 期：5
• 页码：804-812
• 全文大小：480 K

文摘

Background

Hepatectomy is the first-line treatment for alveolar echinococcosis (AE) if complete resection is feasible. However, a strategy for the treatment of patients with AE in whom the tumor cannot be resected completely remains to be defined.

Study Design

Data were retrospectively collected from 188 consecutive patients between 1984 and 2009. Overall survival (OS), progression-free survival (PFS), and risk factors were analyzed in patients classified into 3 groups (group A: complete resection, group B: reduction surgery, and group C: drainage or exploratory laparotomy).

Results

In group A (n = 119), the 10-, 15-, and 20-year OS was 98.9 % . In group B (n = 63), the 10-, 15-, and 20-year OS was 97.1 % , 92.8 % , and 61.9 % . In group C (n = 6), the 10- and 15-year OS was 50.0 % and 33.3 % . Patients in groups A and B had better prognoses than those in group C (p < 0.001). In group A, the 10-, 15-, and 20-year PFS was 96.5 % , 94.4 % , and 94.4 % . In group B, the 10-, 15-, and 20-year PFS was 87.1 % , 71.6 % , and 61.4 % . In group C, the 10- and 15-year PFS was 50.0 % and 33.3 % . Patients in group A had better PFS than those in groups B and C (p < 0.001). Curability was the only independent factor for both OS and PFS by multivariate analysis.

Conclusions

Although the most effective therapy for AE is complete resection, a better prognosis can be achieved by reduction surgery and/or adjuvant albendazole therapy for patients with AE that cannot be completely resected.